Axsome Therapeutics (NASDAQ:AXSM) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report released on Tuesday,RTT News reports.

Other equities research analysts have also recently issued reports about the company. Bank of America lifted their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Robert W. Baird lifted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a report on Monday, February 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $139.00 target price on shares of Axsome Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $190.00 target price on shares of Axsome Therapeutics in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $147.13.

Axsome Therapeutics Stock Down 2.3 %

Shares of Axsome Therapeutics stock opened at $128.09 on Tuesday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.18. The business has a fifty day simple moving average of $98.47 and a 200 day simple moving average of $93.68. The stock has a market cap of $6.21 billion, a PE ratio of -19.62 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. Research analysts predict that Axsome Therapeutics will post -4.7 EPS for the current year.

Insider Activity

In related news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.40% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AXSM. Raiffeisen Bank International AG bought a new stake in Axsome Therapeutics during the fourth quarter worth about $51,000. Assetmark Inc. bought a new stake in Axsome Therapeutics during the fourth quarter worth about $52,000. R Squared Ltd bought a new stake in Axsome Therapeutics during the fourth quarter worth about $64,000. Aquatic Capital Management LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth approximately $76,000. Finally, KBC Group NV increased its position in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after buying an additional 385 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.